Merck & Co. could get an impressive six new prescription medicines approved in the U.S. this year and will soon apply for regulatory approval of two others.
That is the word from company executives who addressed analysts during a briefing Tuesday on Merck’s business.
In addition, Merck is running late-stage patient tests of promising experimental drugs for HIV and hepatitis C, and it’s aiming to be a leader in a hot new area of cancer research called immuno-oncology. Merck and several rivals are trying to develop drugs that fight cancer essentially by stimulating the immune system to identify and attack cancer cells.
The news was overshadowed by the announcement that Merck, based in Whitehouse Station, New Jersey, has agreed to sell its consumer health business to Bayer AG for $14.2 billion.